| Code | CSB-RA624104MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Netakimab, specifically targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune-mediated pathological processes. IL-17A is primarily produced by Th17 cells and plays a crucial role in host defense against extracellular pathogens, but its dysregulation contributes to the pathogenesis of various autoimmune and inflammatory conditions. Elevated IL-17A levels are associated with psoriasis, psoriatic arthritis, ankylosing spondylitis, and other chronic inflammatory diseases, where it promotes neutrophil recruitment, induces pro-inflammatory mediators, and drives tissue inflammation.
Netakimab is a humanized IgG1 monoclonal antibody that selectively binds to IL-17A, neutralizing its biological activity and preventing interaction with IL-17 receptors. This biosimilar antibody serves as a valuable research tool for investigating IL-17A-mediated signaling pathways, exploring cytokine networks in inflammatory disease models, and studying therapeutic mechanisms of IL-17A inhibition. It supports immunological research, drug development studies, and mechanistic investigations of autoimmune disorders.
There are currently no reviews for this product.